Possible involvement of interleukin-31 in pruriginosa-type recessive dystrophic epidermolysis bullosa: a positive response to nemolizumab
Clinical and Experimental Dermatology · 27.10.2026 · 51 (11) · 2100-2102
DOI: 10.1093/ced/llag186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 28.04.2026. Verfasst von Nana Ebi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Selective inhibition of interleukin (IL)-31 led not only to rapid relief of severe pruritus but also to dramatic improvement of inflammatory skin lesions in pruriginosa-type recessive dystrophic epidermolysis bullosa in a boy in early adolescence. While IL-31 is well recognized as a central mediator of itch, this clinical course suggests that IL-31 functions as a disease-amplifying switch linking immune activation, scratching behaviour and cutaneous damage. Interrupting this pathway appeared to collapse the itch–scratch cycle itself, resulting in sustained clinical improvement beyond symptomatic itch control.
Autor:innen und Institutionen
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Dermatology, Asahikawa Medical University, Hokkaido, Japan.
- Department of Dermatology, Hirosaki University School of Medicine, Aomori, Japan.
ORCID-Profile: Toshiaki Kogame, Kenji Kabashima
Zitieren
APA
Ebi, N., Kogame, T., Ishida-Yamamoto, A., Akasaka, E., & Kabashima, K. (2026). Possible involvement of interleukin-31 in pruriginosa-type recessive dystrophic epidermolysis bullosa: a positive response to nemolizumab. Clinical and Experimental Dermatology, 51(11), 2100-2102. https://doi.org/10.1093/ced/llag186
Vancouver
Ebi N, Kogame T, Ishida-Yamamoto A, Akasaka E, Kabashima K. Possible involvement of interleukin-31 in pruriginosa-type recessive dystrophic epidermolysis bullosa: a positive response to nemolizumab. Clinical and Experimental Dermatology. 2026;51(11):2100-2102. doi:10.1093/ced/llag186
BibTeX
@article{Ebi2026,
author = {Ebi, Nana and Kogame, Toshiaki and Ishida-Yamamoto, Akemi and Akasaka, Eijiro and Kabashima, Kenji},
title = {Possible involvement of interleukin-31 in pruriginosa-type recessive dystrophic epidermolysis bullosa: a positive response to nemolizumab},
journal = {Clinical and Experimental Dermatology},
year = {2026},
volume = {51},
number = {11},
pages = {2100--2102},
doi = {10.1093/ced/llag186}
}
EUVIMED